In OCTAVE induction 1 and 2 trials, the primary endpoint was the remission at 8 weeks, and the superiority of tofacitinib (10 mg b
In OCTAVE induction 1 and 2 trials, the primary endpoint was the remission at 8 weeks, and the superiority of tofacitinib (10 mg b.i.d.) versus placebo was exhibited. small molecule, tofacitinib, ulcerative colitis 1. Introduction Ulcerative colitis (UC) is usually a chronic disorder characterized by an inflammatory pattern that usually starts from the rectum and […]
Recent Comments